Phibro Animal Health Corporation (NASDAQ:PAHC) Given Average Recommendation of "Reduce" by Analysts

Key Points

• Phibro Animal Health Corporation (NASDAQ: PAHC) has an average analyst recommendation of "Reduce", with two analysts recommending a sell, four a hold, and one a buy rating.
• The company's stock price target among brokers is set at an average of $28.40, reflecting mixed outlooks from various equity analysts.
• Phibro recently announced a quarterly dividend of $0.12 per share, with a dividend yield of 1.2%, and a payout ratio of approximately 40.68%.

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) have received a consensus rating of "Reduce" from the seven ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $28.40.

Several equities research analysts have issued reports on PAHC shares. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. BNP Paribas upgraded shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Morgan Stanley set a $34.00 price objective on shares of Phibro Animal Health in a research note on Thursday, August 28th. Zacks Research downgraded shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 28th. Finally, Bank of America upped their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $38.42 on Wednesday. Phibro Animal Health has a one year low of $16.16 and a one year high of $41.57. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The company has a 50 day moving average price of $33.16 and a 200 day moving average price of $26.29. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of 32.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.89.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Sell-side analysts anticipate that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be paid a $0.12 dividend. The ex-dividend date is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health's dividend payout ratio is 40.68%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 14,080 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $40.33, for a total value of $567,846.40. Following the completion of the transaction, the chief executive officer directly owned 45,400 shares in the company, valued at approximately $1,830,982. This represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 24,622 shares of company stock valued at $995,893 in the last ninety days. 50.07% of the stock is currently owned by corporate insiders.

Institutional Trading of Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. increased its holdings in shares of Phibro Animal Health by 31.2% in the 4th quarter. Ameriprise Financial Inc. now owns 90,782 shares of the company's stock worth $1,906,000 after acquiring an additional 21,576 shares during the period. Cetera Investment Advisers bought a new position in Phibro Animal Health in the 4th quarter valued at about $204,000. Deutsche Bank AG grew its position in Phibro Animal Health by 90.8% in the 4th quarter. Deutsche Bank AG now owns 16,873 shares of the company's stock valued at $354,000 after buying an additional 8,032 shares in the last quarter. Lazard Asset Management LLC grew its position in Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after buying an additional 1,589 shares in the last quarter. Finally, Millennium Management LLC grew its position in Phibro Animal Health by 233.0% in the 4th quarter. Millennium Management LLC now owns 207,749 shares of the company's stock valued at $4,363,000 after buying an additional 145,359 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.